Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 22.1% in February

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 344,000 shares, an increase of 22.1% from the February 13th total of 281,700 shares. Based on an average trading volume of 236,200 shares, the days-to-cover ratio is presently 1.5 days. Currently, 7.5% of the company’s stock are short sold.

Vivos Therapeutics Stock Performance

NASDAQ:VVOS opened at $3.55 on Wednesday. The firm has a market cap of $20.91 million, a price-to-earnings ratio of -0.62 and a beta of 7.47. Vivos Therapeutics has a 52 week low of $1.91 and a 52 week high of $6.28. The firm has a 50-day moving average price of $4.04 and a two-hundred day moving average price of $3.57.

Analyst Ratings Changes

Several brokerages recently weighed in on VVOS. Alliance Global Partners dropped their price target on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Ascendiant Capital Markets reiterated a “buy” rating and issued a $6.60 price objective on shares of Vivos Therapeutics in a research note on Wednesday, November 20th.

Institutional Investors Weigh In On Vivos Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VVOS. Cutter & CO Brokerage Inc. purchased a new stake in Vivos Therapeutics in the 4th quarter valued at about $163,000. Commonwealth Equity Services LLC increased its stake in shares of Vivos Therapeutics by 23.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock worth $112,000 after purchasing an additional 5,000 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Vivos Therapeutics by 55.6% during the 4th quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock worth $192,000 after purchasing an additional 16,025 shares during the last quarter. Finally, Anson Funds Management LP purchased a new stake in shares of Vivos Therapeutics during the 4th quarter worth approximately $1,041,000. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.